Page 162 - pharma 1 theoretical updated MNU_Neat

Clinical pharmacy 2024/2025 Level 3 Pharm D Pharmacology 1 (PO 502)

Streptokinase

➢ protein purified from culture broths of Group C β-hemolytic streptococci bacteria.
➢ Alone it has no intrinsic enzymatic activity.

To be active:
1. It forms 1:1 complex with plasminogen.
2. This complex act to convert uncomplexed plasminogen to the active fibrinolytic
enzyme plasmin which degrades fibrin

 ADRs

 Hypotension, Allergic reactions (immunogenic), Bleeding tendency

:
 Advantages
.
 mortality and morbidity associated with thromboembolic disorders
 Relatively inexpensive to other thrombolytics.

Urokinase

 The same action of streptokinase but differs in:

➢ Originally isolated from human urine
➢ More expensive than streptokinase.
➢ Non allergic (Non-immunogenic).

➢ Lower recurrence rate of thrombosis.

Intrinsic or tissue-plasminogen activators (t-PA)

 Newly advanced agents & fibrin specific.
➢ Include:

 Alteplase
 Reteplase
 Tenecteplase (TNKase): The fastest lytic bolus injection used in MI
➢ They activate plasminogen bound to fibrin forming plasmin.

| P a g e 146